TGFB1 and glioblastoma: A contrary study in a syngeneic mouse GBM model (4C8) showed that TGFβ1 administration prior to rQNestin34.5 prolonged survival, whereas anti-TGFβ antibody (ID11) abrogated the effect of rQNestin34.5 alone, which was also seen in a human GBM stem-like cell xenograft model [49].